Non‐Canonical Function of DDX21 in Fetal Hematopoiesis Antagonizes KDM5A‐Mediated Repression of Ribosomal and Hematopoietic Genes
Abstract
ABSTRACT Ribosome biogenesis is crucial for meeting the elevated biosynthetic demands of rapidly expanding fetal hematopoietic stem and progenitor cells (HSPCs) during fetal development. Ddx21 is a DEAD‐box RNA helicase required for ribosome biogenesis, but its role in fetal hematopoiesis remains undefined. Here, we show that hematopoietic‐specific deletion of Ddx21 in mice results in severe fetal anemia, HSPC depletion, and loss of reconstitution capacity. Mechanistically, Ddx21 directly binds the histone demethylase Kdm5a via its helicase D2 domain in an RNA‐dependent manner. Ddx21 and Kdm5a co‐occupy active promoters of hematopoietic genes (Gata1, cKit) and rDNA. Unexpectedly, Ddx21 loss does not displace Kdm5a from chromatin but reduces H3K4me3 at these loci, repressing both hematopoietic and ribosomal gene transcription. Although p53 activation drives apoptosis, p53 inhibition only partially rescues hematopoietic failure. Notably, combined pharmacological inhibition of Kdm5a and p53 synergistically restores H3K4me3, protein synthesis, and HSPC colony formation. Our findings reveal a non‐canonical function of Ddx21 in epigenetic regulation by counteracting Kdm5a‐mediated repression to sustain active transcription. The DDX21‐KDM5A complex represents a previously unrecognized chromatin modulator balancing ribosome biogenesis and epigenetic repression, with implications for understanding the pathogenesis of ribosomopathies and developing therapeutic strategies targeting the epigenome‐ribosome interface.